No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HCAT240517P5000
- 0.04
- 0.000.00%
15min DelayTrading May 10 14:01 ET
0.00High0.00Low
0.00Open0.04Pre Close0 Volume1.64K Open Interest5.00Strike Price0.00Turnover346.72%IV-28.48%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.04Time Value100Contract SizeAmericanOptions Type-0.0557Delta0.0726Gamma173.38Leverage Ratio-0.0387Theta0.0000Rho-9.66Eff Leverage0.0005Vega
Intraday
- 5D
- 1D
News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Health Catalyst First Quarter 2024 Earnings: EPS Misses Expectations
Health Catalyst Inc (HCAT) Q1 2024 Earnings: Modest Revenue Growth and Strategic Financial ...
Health Catalyst | 10-Q: Quarterly report
Health Catalyst Is Maintained at Overweight by Wells Fargo
Health Catalyst Is Maintained at Overweight by Wells Fargo
Wells Fargo: Maintaining the Health Catalyst (HCAT.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $14.00 to $13.00.
Wells Fargo: Maintaining the Health Catalyst (HCAT.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $14.00 to $13.00.